scholarly journals Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series

2021 ◽  
Author(s):  
Mila S. Welling ◽  
Cornelis J. Groot ◽  
Lotte Kleinendorst ◽  
Bibian Voorn ◽  
Jan Steven Burgerhart ◽  
...  
Keyword(s):  
Case Series ◽  
Genetic Obesity ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Effects of Glucagon-Like-Peptide-1 analogue treatment in genetic obesity

2021 ◽  
Author(s):  
Mila Welling ◽  
Cornelis de Groot ◽  
Lotte Kleinendorst ◽  
van der Voorn Bibian ◽  
Jansteven Burgerhart ◽  
...  
Keyword(s):  
Genetic Obesity ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A33-A34
Author(s):  
Mila Sofie Welling ◽  
Cornelis J de Groot ◽  
Lotte Kleinendorst ◽  
Bibian van der Voorn ◽  
Jan Steven Burgerhart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Weight Loss ◽  
Side Effects ◽  
Metabolic Parameters ◽  
Deletion Syndrome ◽  
Genetic Obesity ◽  
Lifestyle Treatment ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Abstract Introduction: Obesity is highly prevalent, comes with serious health burden and is difficult to treat. In a minority, there is a genetic cause for the obesity. In these patients, therapy-resistant obesity is often observed despite intensive lifestyle treatment. Moreover, it is still unclear whether bariatric surgery is less successful in genetic obesity. Liraglutide is a Glucagon-Like-Peptide-1 (GLP-1) receptor agonist or GLP-1 analogue, showing positive effects on metabolic parameters, satiety and weight loss in lifestyle-induced obesity. We present our experiences of GLP-1 analogue treatment in patients with genetic obesity disorders. Methods: Adults with overweight or severe obesity and a molecularly proven genetic cause were treated with liraglutide 3,0 mg daily, in addition to ongoing intensive supportive lifestyle treatment. Anthropometrics, metabolic parameters, resting energy expenditure (REE), side effects, and subjectively reported satiety and quality of life were assessed. Results: Two patients with a heterozygous pathogenic melanocortin 4 recepter variant and two patients with 16p11.2 deletion syndrome, ranging in age between 21 and 32 years and in BMI between 28.1 and 55.7 kg/m2 at baseline, were treated. At end of follow-up, ranging between 33 weeks and 12 years, a mean change in BMI and waist circumference was observed of -5.7 ± 3.8 kg/m2 and -15.2 ± 21.1 cm, respectively. All patients reported better quality of life, three of them also reported improved satiety. Moreover, improvement of metabolic parameters was seen. No clear effect on REE was observed. Two patients experienced mild side effects, e.g. nausea and stomach pain, for a brief period. Conclusion: We here show beneficial effects of GLP-1 analogues on weight, metabolic parameters, and quality of life in four patients with genetic obesity. Satiety improved in three of the four patients. All patient achieved at least the clinically relevant 5–10% weight loss. Our findings suggest that GLP-1 analogue treatment might be an effective treatment option, in addition to a healthy lifestyle, for patients with genetic obesity.

scholarly journals Effects of Combination of SGLT-2 Inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria : A Case Series

2020 ◽  
Author(s):  
Nitesh Kuhadiya ◽  
Israa Mahmood
Keyword(s):  
Combination Therapy ◽  
Receptor Agonist ◽  
Case Series ◽  
Renal Outcome ◽  
Renal Protection ◽  
Estimated Gfr ◽  
Risk Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

We hypothesized that the combination therapy of SGLT-2(Sodium-glucose co-transporter-2)inhibitor and Glucagon-like peptide-1 receptor agonist(GLP-1RA) provide renal protection in adults with T2D with estimated GFR (eGFR) below 30ml/minute/1.73 m2. We hereby describe four consecutively treated high renal risk patients with T2D with eGFR between 21 to 30ml/minute/1.73m2.

Effects of glucagon-like peptide-1 (GLP-1) on gastric accommodation, emptying and satiety in humans

2001 ◽  
Vol 120 (5) ◽  
pp. A74-A74
Author(s):  
S AROS ◽  
D KIM ◽  
D BURTON ◽  
G THOMFORDE ◽  
A VELLA ◽  
...  
Keyword(s):  
Gastric Accommodation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Eine häufige genetische Variation in WFS1 bedingt eine gestörte Glucagon-like Peptide-1-induzierte Insulinsekretion

2009 ◽  
Vol 4 (S 01) ◽  
Author(s):  
K Müssig ◽  
SA Schäfer ◽  
H Staiger ◽  
F Machicao ◽  
N Stefan ◽  
...  
Keyword(s):  
Genetische Variation ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document